Micardis patents expiration

MICARDIS's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8003679 BOEHRINGER INGELHEIM Use of inhibitors of the renin-angiotensin system
Oct, 2022

(11 months ago)

Micardis is owned by Boehringer Ingelheim.

Micardis contains Telmisartan.

Micardis has a total of 1 drug patent out of which 1 drug patent has expired.

Expired drug patents of Micardis are:

  • US8003679

Micardis was authorised for market use on 10 November, 1998.

Micardis is available in tablet;oral dosage forms.

Micardis can be used as treatment or prevention of stroke.

The generics of Micardis are possible to be released after 06 October, 2022.

Drugs and Companies using TELMISARTAN ingredient

Market Authorisation Date: 10 November, 1998

Treatment: Treatment or prevention of stroke


How can I launch a generic of MICARDIS before it's drug patent expiration?
More Information on Dosage

MICARDIS family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic